Revolution Medicines (RVMD) Cash & Equivalents (2018 - 2026)

Revolution Medicines has reported Cash & Equivalents for 9 years, with the latest figure at $440.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 32.19% year-over-year to $440.9 million; the trailing twelve-month figure through Mar 2026 stood at $440.9 million (up 32.19% YoY), and the FY2025 full-year result was $383.7 million, down 29.34% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $440.9 million, up from $383.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $696.1 million in Q4 2023, with the low at $97.7 million in Q1 2022.
• Average Cash & Equivalents over 5 years is $323.1 million, with a median of $333.6 million recorded in 2025.
• Year-over-year, Cash & Equivalents plunged 72.22% in 2022 and surged 337.43% in 2023.
• Tracing RVMD's Cash & Equivalents over 5 years: stood at $161.4 million in 2022, then jumped by 331.29% to $696.1 million in 2023, then decreased by 21.99% to $543.1 million in 2024, then declined by 29.34% to $383.7 million in 2025, then grew by 14.9% to $440.9 million in 2026.
• The last three Cash & Equivalents figures came in at $440.9 million (Q1 2026), $383.7 million (Q4 2025), and $217.4 million (Q3 2025), per Business Quant data.

Peer Comparison